Nasal spray similar to ketamine to be added to PBS for treatment-resistant depression
A medication chemically similar to ketamine will be made cheaper to improve the lives of Australians suffering from treatment-resistant depression.
The drug, which comes in the form of a nasal spray, is a chemical cousin of ketamine, used for decades as a powerful anaesthetic before it was adopted as a party drug in underground rave culture.
There have been no major pharmaceutical innovations for depression since the launch of Prozac and related antidepressants in the late 1980s.
Those drugs target the 'feel-good' brain chemical serotonin and can take weeks or months to kick in.
Sign up for the Afternoon Update: Election 2025 email newsletter
Spravato, known chemically as esketamine, works differently. It targets a neurotransmitter called glutamate that is thought to restore brain connections that help relieve depression.
When it works, its effect can be felt within a matter of hours, according to Prof Ian Hickie of the University of Sydney. The co-director of Health and Policy at the University of Sydney's Brain and Mind Centre has been working with the drug for a small number of patients under a special access scheme.
But from Thursday, it will be available and affordable for up to 30,000 Australians through the Pharmaceutical Benefits Scheme.
It will also mark the first new type of medicine for major depression to be funded by the government in three decades.
'Most of the drug development we've had in the last three decades has mimicked what had preceded it,' Hickie said. 'This is different ... it targets a different neurochemical system – glutamate – and appears to regulate those brain circuits that regulate mood in a different way.'
Australian trials using the ketamine-like drug have shown significant improvement in about 50% of people who had otherwise been resistant to conventional treatments.
'Not all depression is the same, nor does it have the same chemical explanation in all people,' Hickie said.
'For some people, particularly those who have failed to respond to the conventional serotonin-focused agents, or monoamine-focused agents, this is different and they appear to benefit.'
Sign up to Afternoon Update: Election 2025
Our Australian afternoon update breaks down the key election campaign stories of the day, telling you what's happening and why it matters
after newsletter promotion
Since the drug was approved for use by the Food and Drug Administration in 2019, it has been commonly used in emergency rooms and other urgent care settings across the US.
'Here's something that actually works quickly, not by knocking you out, not by sedating you, but by alleviating that terrible sense of hopelessness and terrible depressiveness and to some degree that sense of suicidality,' Hickie said.
Spravato will be available through the scheme at a cost per dose of $31.60 or $7.70 for pensioners and concession card holders. However, patients will need to incur additional healthcare and administration costs, including supervision by a healthcare professional at a certified treatment centre.
The minister for health and aged care, Mark Butler, said the listing would make the novel drug more affordable and improve the quality of life for thousands of Australians.
Johnson & Johnson's innovative medicine ANZ managing director, Joana De Castro, said the 'long overdue' listing came after four funding submissions and a four-year wait following Therapeutic Goods Administration registration.
Crisis support services can be reached 24 hours a day: Lifeline 13 11 14; Suicide Call Back Service 1300 659 467; Kids Helpline 1800 55 1800; MensLine Australia 1300 78 99 78; Beyond Blue 1300 22 4636
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
a day ago
- NBC News
Four states petition the FDA to lift abortion pill restrictions
Four states petitioned the Food and Drug Administration on Thursday to lift its lingering restrictions on abortion pills. The attorneys general of California, Massachusetts, New Jersey and New York argue in the petition that the FDA's current regulations make it difficult to prescribe mifepristone — one of two pills involved in a medication abortion — in primary care settings, despite evidence that it's safe to do so. 'Given mifepristone's 25-year safety record, there is simply no scientific or medical reason to subject it to such extraordinary restrictions,' New York Attorney General Letitia James said in a statement. 'The FDA must follow the science and lift these unnecessary barriers that put patients at risk and push providers out of care.' The drug is a central flash point in the abortion debate. Many anti-abortion groups see restricting who can get mifepristone or rescinding its approval as one of the most effective ways to limit abortion access nationwide. The petition comes just days after FDA Commissioner Marty Makary said he was committed to conducting a safety review of mifepristone. Health and Human Services Secretary Robert F. Kennedy Jr. and Sen. Josh Hawley, R-Mo., each requested the review following the release of a paper, which was neither peer-reviewed nor published in a medical journal, that claimed to find a high rate of serious adverse events in women who recently took the medication. Researchers who study reproductive health said the report amounts to junk science and exaggerates the risks of mifepristone. They note that it does not meet basic research standards, relying on overly broad definitions and failing to disclose which database it used. The report was released by the Ethics and Public Policy Center, a conservative think tank that served on the advisory board of Project 2025, a right-wing policy initiative that called for the FDA to walk back its approval of mifepristone. The attorneys general said Thursday that the FDA should use the safety review as an opportunity to remove barriers to accessing mifepristone nationwide — or, at minimum, in the four states involved in the petition. The FDA regulates certain medications with serious safety concerns via a drug safety program called Risk Evaluation and Mitigation Strategies (REMS). Mifepristone is currently part of that program, though a wealth of research has shown that less than 0.5% of women who take it have serious adverse reactions. Studies have also demonstrated that prescribing mifepristone through telehealth is as safe and effective as administering it in person. As part of the REMS program, mifepristone is subject to a few restrictions: People who prescribe the pills must be certified health care providers, and pharmacies must obtain certifications to dispense the medication. Patients who receive mifepristone must also sign a form attesting that they intend to end their pregnancy. The attorneys general said in their petition that those restrictions are burdensome and unnecessary. They claim that many primary care and family medicine physicians aren't able or willing to take on the administrative burden of getting certified to prescribe the pills, or are worried about being added to a list of national or local abortion providers. The FDA has already lifted several restrictions on mifepristone over the last decade. In 2016, it extended the window in which mifepristone could be used to terminate pregnancies from seven weeks' gestation to 10 weeks. In 2019, it approved a generic form of the medication, which increased supply. And in 2021, it eliminated a requirement to dispense mifepristone in person, allowing the drug to be prescribed via telehealth and sent by mail. Anti-abortion groups have called on the FDA to reinstate those restrictions, often pointing to misleading studies that suggest the medication has harmful effects. The April report that launched the FDA safety review, for instance, claims to find a 22-times higher rate of serious complications from mifepristone than reported by the agency. In their petition Thursday, the four attorneys general denounced recent attempts to challenge mifepristone's safety, which they said rely on methodologically flawed research. A coalition of anti-abortion groups sued the FDA in 2022 over its approval of mifepristone, citing two studies from the Charlotte Lozier Institute, a group that opposes abortion, that claimed to show severe complications from the drug. The lawsuit was ultimately thrown out by the Supreme Court and the studies were later retracted by a medical publisher. The Charlotte Lozier Institute released another paper last month claiming that a growing number of emergency room visits after abortions are incorrectly attributed to miscarriages, thereby masking abortion complications. Rachel Jones, a principal research scientist at the Guttmacher Institute, a research organization that supports abortion access, said the data only captures a small portion of abortions and is skewed in favor of those that are potentially higher risk. Some of the same data was used in the retracted studies, she said. Jones added that the timing of the new reports from anti-abortion groups is not coincidental. 'The anti-choice people are really going after medication abortion and doing whatever they can to get the FDA under the Trump administration to revisit the availability of the drug,' she said.
Reuters
a day ago
- Reuters
New York, other states urge FDA to expand access to abortion pill
NEW YORK, June 5 (Reuters) - The attorneys general of New York, California, Massachusetts and New Jersey asked the Food and Drug Administration to expand access to the abortion pill mifepristone, and remove outdated restrictions still in place 25 years after its approval. Thursday's petition came after Health and Human Services Secretary Robert F. Kennedy Jr told Congress last month he directed FDA Commissioner Marty Makary to review the pill, saying "alarming" new data suggested at minimum that the label should be changed. Mifepristone, together with the drug misoprostol, won FDA approval in 2000 for medication abortion in the first 10 weeks of pregnancy. Medication abortions account for more than half of U.S. abortions, though 28 states restrict access according to the nonprofit Guttmacher Institute, which focuses on reproductive health. The petition challenges FDA requirements that mifepristone prescribers be included in national and local abortion provider lists, patients attest in writing that they intend to end their pregnancies, and pharmacies perform a variety of recordkeeping. New York Attorney General Letitia James said the FDA's Risk Evaluation and Mitigation Strategy program imposes "medically unnecessary" rules that keep mifepristone out of reach of most primary care settings. She called the problem particularly acute in rural and other areas where getting abortions often requires lengthy travel. "There is simply no scientific or medical reason to subject it to such extraordinary restrictions," James said, referring to mifepristone. "The FDA must follow the science." Many states, primarily Republican-led or leaning, have restricted or substantially eliminated abortions in the three years since the U.S. Supreme Court overturned Roe v. Wade, the 1973 decision that legalized the procedure nationwide. The White House under Republican President Donald Trump has largely sided with abortion opponents, though Trump said during his 2024 campaign he did not plan to limit access to mifepristone. Last month, the administration asked a federal judge to dismiss, on procedural grounds, a lawsuit by three generally Republican states seeking to narrow such access. That lawsuit began during the administration of Democratic President Joe Biden, who generally supported abortion access. Seventeen other Democratic-led or -leaning states plus Washington, D.C. are separately suing the FDA in Spokane, Washington to loosen restrictions on mifepristone. They said doctors and pharmacies should be able to dispense the pill, as with most drugs, without special certifications. On May 30, the Trump administration urged a dismissal, saying the states didn't show the FDA's policy was flawed or the agency ignored important evidence.
Scottish Sun
a day ago
- Scottish Sun
‘It took years off my life' – Fabio Wardley lived off ice cream and noodles after brutal Frazer Clarke fight
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) FABIO WARDLEY resorted to a diet of ice cream and noodles after his brutal fight against Frazer Clarke. The pair put on a thriller over 12 rounds in March of last year - which ended in a draw. Sign up for Scottish Sun newsletter Sign up 5 Fabio Wardley's horror nose injury against Frazer Clarke Credit: Getty 5 He was unable to chew for days afterwards Credit: PA 5 The bout ended a draw with Wardley winning the rematch by KO Credit: Reuters Wardley was left covered in blood due to his busted nose and a jaw injury left him barely able to chew in the days after. He told The Times: 'It's a fate that you have to accept if you do this sport properly. "I probably should've gone to the hospital afterwards. I remember being sat in my hotel room and I couldn't sleep because my head was pounding, like vibrating. "When I lay down, I felt sick. If I sat up, I felt sick. My face looked like the Elephant Man. My nose was stitched up. READ MORE IN BOXING 'I was confused' Wardley thought he was being SCAMMED when Usyk asked him for sparring "I'd bitten my tongue about 100 times. I couldn't chew for three days because of my jaw, so I just ate ice cream and noodles, but that's part of it. "Those fights are going to happen and you might get knocked out, but if you carry that around with you and hesitate because you're scared of it, it could have a negative impact on how you fight and almost make it more likely to happen. You've got to just take it on the chin.' Wardley scored a knockdown in round five and Clarke had a point off to even the judges scorecards. But Wardley won the rematch six months later with a brutal first-round knockout that left Clarke hospitalised. 5 CASINO SPECIAL - BEST CASINO BONUSES FROM £10 DEPOSITS Now the Ipswich super-fan returns on Saturday at Portman Road against Australian Justis Huni. Huni won the amateur World Youth Championships in 2016 - the same year Wardley had his first unlicensed white collar bout. Fabio Wardley prepares for dream Portman Road homecoming fight Wardley said: 'Huni is another opponent from a completely different end of entry in boxing terms. 'After starting in white-collar, anything was a win. This wasn't realistic, but you always imagine.' Wardley had four fights on the unlicensed circuit - winning them all by KO - after foregoing an amateur career. Now he is on the cusp of a world title shot as part of one of British boxing's most unlikely success stories. Wardley said: 'I fought at the O2, then I headlined the O2, I've fought in Saudi Arabia as the chief support to Tyson Fury and to Artur Beterbiev vs Dmitry Bivol. "It keeps feeling like we've peaked and that it can't get any better and now I'm fighting at the stadium in my hometown. "I'm genuinely on the edge of a world title, which sounds crazy for me just to say.'
